modelL01CA03
Extends from Pharmacokinetic.Models.PK_2C.
Information
| name: | Vindesine | |
| ATC code: | L01CA03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 3.0 | mg |
| volume of distribution: | 34.5 | L |
| clearance: | 294.0 | ml/min |
| other parameters in model implementation | ||
Vindesine is a semi-synthetic vinca alkaloid chemotherapeutic agent, structurally related to vincristine and vinblastine. It disrupts microtubule formation, inhibiting mitosis in cancer cells. Vindesine has been used primarily in the treatment of various malignancies, including acute lymphoblastic leukemia, malignant melanoma, breast cancer, and lung cancer. While it has seen global use since its introduction, vindesine is now less commonly used and is not approved in certain countries, such as the United States.
Pharmacokinetics
PK parameters reported in adult cancer patients receiving intravenous vindesine, from non-compartmental and compartmental pharmacokinetic studies.
References
Zhu, RH, et al., & Peng, WX (2014). Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. Journal of pharmaceutical and biomedical analysis 96 31–36. DOI:10.1016/j.jpba.2014.03.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24721203
Tran, L, et al., & Huitema, AD (2010). Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Human antibodies 19(1) 7–13. DOI:10.3233/HAB-2010-0215 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20555126
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)